乳がんリキッドバイオプシー検査機器市場：提供、循環バイオマーカー、エンドユーザー、用途別-2025年～2030年の世界予測

乳がんリキッドバイオプシー検査機器市場は、2023年に8億5,876万米ドルと評価され、2024年には10億2,360万米ドルに達すると予測され、CAGR 19.59%で成長し、2030年には30億457万米ドルに達すると予測されています。

乳がんリキッドバイオプシー検査機器の範囲と定義には、血液中を循環する腫瘍からがん細胞やDNAを検出するように設計された診断ツールが含まれ、従来の生検に代わる非侵襲的な方法を提供します。これらの機器は、がんの早期発見、病状の進行のモニタリング、治療計画の個別化に不可欠であり、精密医療に不可欠です。用途は臨床診断、治療モニタリング、予後予測に及び、最終用途は病院、診断研究所、研究機関などです。乳がんリキッドバイオプシー市場を牽引する主な成長要因は、がん罹患率の増加、非侵襲的手技に対する需要の高まり、分子生物学技術の進歩などです。最近の潜在的なビジネスチャンスは、データ解析の精度を高めるための人工知能と機械学習の統合や、特にヘルスケアインフラが整備されつつある発展途上地域における早期発見やリアルタイムモニタリングへの応用拡大にあります。しかし、市場は、高度な検査にかかる高コスト、規制上のハードル、開業医や患者の限られた認識といった限界に直面しています。検査の感度と特異度に関する課題に対処することは、より広範な普及のために引き続き極めて重要です。技術革新に最適な分野としては、バイオマーカー探索の改善、運用コストの削減、次世代シーケンシングやその他のゲノム技術による検査予測能力の強化などが挙げられます。乳がんの不均一性とその複雑な生物学に関する調査は、これらの検査機器の有効性をさらに最適化する可能性があります。市場は本質的にダイナミックであり、急速な技術進化と従来の生検方法からの競争圧力があります。企業は競争力を維持するために、共同研究パートナーシップ、個別化医療のためのビッグデータの活用、研究開発への投資拡大に注力すべきです。新たなビジネスチャンスを生かすためには、複雑なヘルスケア・システムを巧みに操り、費用対効果の高いソリューションを効率的に市場に投入できるような、教育活動、規制当局への働きかけ、戦略的提携の強化が必要です。

市場力学：急速に進化する乳がんリキッドバイオプシー検査機器市場の主要市場インサイトを公開

乳がんリキッドバイオプシー検査機器市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の女性の乳がん罹患率の上昇
  • 非侵襲的乳がん治療に対する需要の高まり
  • 乳がん発見のための事前スクリーニングプログラムの急増
• 市場抑制要因
  • 検査機器の精度に関する懸念
• 市場機会
  • 乳がんリキッドバイオプシー検査機器における技術の進歩
  • 乳がん検査のための研究開発投資
• 市場の課題
  • リキッドバイオプシーに関する厳格な基準の存在

ポーターの5つの力：乳がんリキッドバイオプシー検査機器市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：乳がんリキッドバイオプシー検査機器市場における外部からの影響の把握

外部マクロ環境要因は、乳がんリキッドバイオプシー検査機器市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析乳がんリキッドバイオプシー検査機器市場における競合情勢の把握

乳がんリキッドバイオプシー検査機器市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス乳がんリキッドバイオプシー検査機器市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、乳がんリキッドバイオプシー検査機器市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨乳がんリキッドバイオプシー検査機器市場における成功への道筋を描く

乳がんリキッドバイオプシー検査機器市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で女性の乳がん罹患率が上昇
    • 非侵襲性乳がん治療の需要増加
    • 乳がん発見のための事前スクリーニングプログラムの急増
  • 抑制要因
    • 検査機器の精度に関する懸念
  • 機会
    • 乳がんリキッドバイオプシー検査機器における技術的進歩
    • 乳がん検査の研究開発への投資
  • 課題
    • 液体生検に対する厳格な基準の存在
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 乳がんリキッドバイオプシー検査機器市場：提供別

• アッセイおよび試薬キット
• 機器

第7章 乳がんリキッドバイオプシー検査機器市場：循環バイオマーカー別

• 循環腫瘍DNA
• 循環腫瘍細胞
• 細胞外小胞

第8章 乳がんリキッドバイオプシー検査機器市場：エンドユーザー別

• 病院
• 調査室

第9章 乳がんリキッドバイオプシー検査機器市場：用途別

• 診断
• 監視
• スクリーニング/早期発見
• 治療の選択

第10章 南北アメリカの乳がんリキッドバイオプシー検査機器市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋の乳がんリキッドバイオプシー検査機器市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの乳がんリキッドバイオプシー検査機器市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Biocept, Inc.
• Biodesix, Inc.
• BioVIew Ltd.
• Eurofins Scientific SE
• Exact Sciences Corporation
• F. Hoffmann-La Roche AG
• Fluxion Biosciences Inc.
• Guardant Health, Inc.
• Illumina, Inc.
• Isogen Life Science B.V.
• Johnson & Johnson Services, Inc.
• Laboratory Corporation of America Holdings
• Lucence Health Inc.
• Menarini Group
• Merck KGaA
• Myriad Genetics, Inc.
• Natera Inc.
• Neogenomics Laboratories, Inc.
• OncoDNA SA
• Qiagen N.V.
• Sysmex Corporation
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET RESEARCH PROCESS
• FIGURE 2. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET DYNAMICS
• TABLE 7. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY ASSAY & REAGENTS KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMAR DNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR CELL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXTRACELLULAR VESICLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY MONITORING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SCREENING/EARLY DETECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TREATMENT SELECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. CANADA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 36. CANADA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 37. CANADA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. CANADA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 58. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 59. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. INDIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 62. INDIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 63. INDIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. INDIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 130. ITALY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 131. ITALY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 132. ITALY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. ITALY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. POLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 147. POLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 148. POLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. POLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 150. QATAR BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 151. QATAR BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 152. QATAR BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 153. QATAR BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
• TABLE 190. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 191. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET, FPNV POSITIONING MATRIX, 2023

The Breast Cancer Liquid Biopsy Testing Devices Market was valued at USD 858.76 million in 2023, expected to reach USD 1,023.60 million in 2024, and is projected to grow at a CAGR of 19.59%, to USD 3,004.57 million by 2030.

The scope and definition of breast cancer liquid biopsy testing devices encompass diagnostic tools designed to detect cancer cells or DNA from tumors circulating in the blood, offering a non-invasive alternative to traditional biopsies. These devices are crucial for early cancer detection, monitoring disease progression, and personalizing treatment plans, making them indispensable in precision medicine. The application scope spans clinical diagnostics, treatment monitoring, and prognosis, with end-use sectors including hospitals, diagnostic laboratories, and research institutions. Key growth factors driving the breast cancer liquid biopsy market include increasing cancer prevalence, rising demand for non-invasive procedures, and advancements in molecular biology technology. Recent potential opportunities lie in the integration of artificial intelligence and machine learning to enhance data analysis accuracy, as well as expanding applications in early-stage detection and real-time monitoring, particularly in developing regions with growing healthcare infrastructure. However, the market faces limitations such as high costs of advanced testing, regulatory hurdles, and limited awareness among practitioners and patients. Addressing challenges around sensitivity and specificity of tests remains crucial for broader adoption. Best areas for innovation include improving biomarker discovery, reducing operational costs, and enhancing the test's predictive capabilities through next-generation sequencing and other genomic technologies. Research into the heterogeneity of breast cancer and its complex biology may further optimize the efficacy of these devices. The market is inherently dynamic, with rapid technological evolution and competitive pressures from traditional biopsy methods. Companies should focus on collaborative research partnerships, leveraging big data for personalized medicine, and increased investment in R&D to maintain a competitive edge. To capitalize on emerging opportunities, there is a need for increasing educational efforts, regulatory advocacy, and strategic alliances that can help navigate complex healthcare systems and bring cost-effective solutions to market efficiently.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Breast Cancer Liquid Biopsy Testing Devices Market

The Breast Cancer Liquid Biopsy Testing Devices Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of breast cancer among women worldwide
  • Increasing demand for non-invasive breast cancer treatment
  • Surge in pre-screening programs for breast cancer detection
• Market Restraints
  • Concerns related to the accuracy of testing devices
• Market Opportunities
  • Technological advancements in breast cancer liquid biopsy testing devices
  • Investments in R&D for breast cancer testing
• Market Challenges
  • Presence of strict standards for liquid biopsy

Porter's Five Forces: A Strategic Tool for Navigating the Breast Cancer Liquid Biopsy Testing Devices Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Breast Cancer Liquid Biopsy Testing Devices Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Breast Cancer Liquid Biopsy Testing Devices Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Breast Cancer Liquid Biopsy Testing Devices Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Breast Cancer Liquid Biopsy Testing Devices Market

A detailed market share analysis in the Breast Cancer Liquid Biopsy Testing Devices Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Breast Cancer Liquid Biopsy Testing Devices Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Breast Cancer Liquid Biopsy Testing Devices Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Breast Cancer Liquid Biopsy Testing Devices Market

A strategic analysis of the Breast Cancer Liquid Biopsy Testing Devices Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Breast Cancer Liquid Biopsy Testing Devices Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocept, Inc., Biodesix, Inc., BioVIew Ltd., Eurofins Scientific SE, Exact Sciences Corporation, F. Hoffmann-La Roche AG, Fluxion Biosciences Inc., Guardant Health, Inc., Illumina, Inc., Isogen Life Science B.V., Johnson & Johnson Services, Inc., Laboratory Corporation of America Holdings, Lucence Health Inc., Menarini Group, Merck KGaA, Myriad Genetics, Inc., Natera Inc., Neogenomics Laboratories, Inc., OncoDNA SA, Qiagen N.V., Sysmex Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Breast Cancer Liquid Biopsy Testing Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Offerings, market is studied across Assay & Reagents Kits and Instruments.
• Based on Circulating Biomarker, market is studied across Circulating Tumar DNA, Circulating Tumor Cell, and Extracellular Vesicles.
• Based on End-User, market is studied across Hospitals and Research Laboratories.
• Based on Appplication, market is studied across Diagnosis, Monitoring, Screening/Early Detection, and Treatment Selection.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of breast cancer among women worldwide
    • 5.1.1.2. Increasing demand for non-invasive breast cancer treatment
    • 5.1.1.3. Surge in pre-screening programs for breast cancer detection
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns related to the accuracy of testing devices
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in breast cancer liquid biopsy testing devices
    • 5.1.3.2. Investments in R&D for breast cancer testing
  • 5.1.4. Challenges
    • 5.1.4.1. Presence of strict standards for liquid biopsy
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Breast Cancer Liquid Biopsy Testing Devices Market, by Offerings

• 6.1. Introduction
• 6.2. Assay & Reagents Kits
• 6.3. Instruments

7. Breast Cancer Liquid Biopsy Testing Devices Market, by Circulating Biomarker

• 7.1. Introduction
• 7.2. Circulating Tumar DNA
• 7.3. Circulating Tumor Cell
• 7.4. Extracellular Vesicles

8. Breast Cancer Liquid Biopsy Testing Devices Market, by End-User

• 8.1. Introduction
• 8.2. Hospitals
• 8.3. Research Laboratories

9. Breast Cancer Liquid Biopsy Testing Devices Market, by Appplication

• 9.1. Introduction
• 9.2. Diagnosis
• 9.3. Monitoring
• 9.4. Screening/Early Detection
• 9.5. Treatment Selection

10. Americas Breast Cancer Liquid Biopsy Testing Devices Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Breast Cancer Liquid Biopsy Testing Devices Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Breast Cancer Liquid Biopsy Testing Devices Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Agilent Technologies, Inc.
• 2. Becton, Dickinson and Company
• 3. Bio-Rad Laboratories, Inc.
• 4. Biocept, Inc.
• 5. Biodesix, Inc.
• 6. BioVIew Ltd.
• 7. Eurofins Scientific SE
• 8. Exact Sciences Corporation
• 9. F. Hoffmann-La Roche AG
• 10. Fluxion Biosciences Inc.
• 11. Guardant Health, Inc.
• 12. Illumina, Inc.
• 13. Isogen Life Science B.V.
• 14. Johnson & Johnson Services, Inc.
• 15. Laboratory Corporation of America Holdings
• 16. Lucence Health Inc.
• 17. Menarini Group
• 18. Merck KGaA
• 19. Myriad Genetics, Inc.
• 20. Natera Inc.
• 21. Neogenomics Laboratories, Inc.
• 22. OncoDNA SA
• 23. Qiagen N.V.
• 24. Sysmex Corporation
• 25. Thermo Fisher Scientific Inc.